Katholieke Universiteit Leuven

Katholieke Universiteit Leuven, Ku Leuven R&d

Consiglio Nazionale Delle Ricerche

Aix-marseille Université

Suzanne Kaptein

Arnaud Marchand

Johan Neyts

Kai Dallmeier

Mohamed Koukni

Dorothée Bardiot

Wim Smets

Gunter Carlens

Michael McNaughton

Xavier De Lamballerie

Eloise Mastrangelo

Martino Bolognesi

Mario Milani De Mayo De Mari

Boris Pastorino

Dorothee Bardiot

Michael Mcnaughton

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

Viral replication inhibitors

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds. 

Avermectin and milbemycin compounds, particularly the substance ivermectin, for preparing an antiviral medicament for the treatment, prevention or amelioration of ainfection, such as those caused by YFV (yellow fever virus), DENV (Dengue virus), JEV (Japanese encephalitis virus), TBEV (tick-borne encephalitis virus) or MODV (Modoc virus) are provided. The antiviral compositions of the present invention are suitable for oral administration to a-infected subject or a subject at risk of a infection, such as a human or other mammal.

Avermectins and milbemycins for the treatment, prevention or amelioration of flavivirus infections

Growing community of inventors

Leuven, Belgium

Suzanne Kaptein